BerGenBio ASA (OSL:BGBIO) Current Accrued Expense : kr0.00 Mil (As of Mar. 2024)

View and export this data going back to 2017. Start your Free Trial

What is BerGenBio ASA Current Accrued Expense?

BerGenBio ASA's Current Accrued Expense for the quarter that ended in Mar. 2024 was kr0.00 Mil.

BerGenBio ASA Current Accrued Expense Historical Data

The historical data trend for BerGenBio ASA's Current Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BerGenBio ASA Current Accrued Expense Chart

BerGenBio ASA Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Current Accrued Expense

Get a 7-Day Free Trial

BerGenBio ASA Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Current Accrued Expense	Get a 7-Day Free Trial															-	-	-	-	-

BerGenBio ASA Current Accrued Expense Calculation

Current Accrued Expense is the expense incurred during the accounting period, but not required to be paid until a later date. It includes compensation, interest, pensions and all other miscellaneous accruals reported by the company.

BerGenBio ASA Current Accrued Expense Related Terms

Thank you for viewing the detailed overview of BerGenBio ASA's Current Accrued Expense provided by GuruFocus.com. Please click on the following links to see related term pages.

BerGenBio ASA (OSL:BGBIO) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BerGenBio ASA (OSL:BGBIO) » Definitions » Current Accrued Expense

Comparable Companies

Traded in Other Exchanges

0RU5:UK 7BG0:Germany

Address

Mollendalsbakken 9, Bergen, NOR, 5009

Website

https://www.bergenbio.com

BerGenBio ASA is a clinical stage oncology biotech company, which is engaged in developing therapeutics against novel drug targets that drive aggressive cancers. Its drug candidate bemcentinib (BGB324) is d is curently being developed in STK11 mutated NSCLC and severe respiratory infections including COVID-19. .

BerGenBio ASA (OSL:BGBIO) Headlines

No Headlines